Trevi Therapeutics, Inc. - TRVI
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 27, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13D/A | — | — | — | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Rubric Capital Management LP | 2.94% | 3,766,749 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | David Rosen | 2.94% | 3,766,749 | View |
| Feb 05, 2026 | SCHEDULE 13G | FMR LLC | 5.1% | 6,500,009 | View |
| Feb 05, 2026 | SCHEDULE 13G | Abigail P. Johnson | 5.1% | 6,500,009 | View |
| Jan 30, 2026 | SCHEDULE 13G | The Vanguard Group | 5.01% | 6,434,655 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | VIKING GLOBAL INVESTORS LP | 4.2% | 5,128,875 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Viking Global Opportunities Parent GP LLC | 4.2% | 5,128,875 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Viking Global Opportunities GP LLC | 2.8% | 3,436,346 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Viking Global Opportunities Portfolio GP LLC | 2.8% | 3,436,346 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Viking Global Opportunities Illiquid Investments Sub-Master LP | 2.8% | 3,436,346 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Viking Global Opportunities Drawdown GP LLC | 1.4% | 1,692,529 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Viking Global Opportunities Drawdown Portfolio GP LLC | 1.4% | 1,692,529 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Viking Global Opportunities Drawdown (Aggregator) LP | 1.4% | 1,692,529 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | HALVORSEN OLE ANDREAS | 4.2% | 5,128,875 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Ott David C. | 4.2% | 5,128,875 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Shabet Rose Sharon | 4.2% | 5,128,875 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Frazier Life Sciences Public Fund, L.P. | 7.0% | 8,508,021 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | FHMLSP, L.P. | 7.0% | 8,508,021 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | FHMLSP, L.L.C. | 7.0% | 8,508,021 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Frazier Life Sciences X, L.P. | 0.3% | 397,309 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | FHMLS X, L.P. | 0.3% | 397,309 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | FHMLS X, L.L.C. | 0.3% | 397,309 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Frazier Life Sciences XI, L.P. | 1.1% | 1,354,079 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | FHMLS XI, L.P. | 1.1% | 1,354,079 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | FHMLS XI, L.L.C. | 1.1% | 1,354,079 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | James N. Topper | 0.3% | 397,309 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Patrick J. Heron | 0.3% | 397,309 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Albert Cha | 0.0% | 0 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | James Brush | 0.0% | 0 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Daniel Estes | 0.0% | 0 | View |
| Oct 17, 2025 | SCHEDULE 13G | BlackRock, Inc. | 5.6% | 6,804,338 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.